Figure 1. Use of First-Line Immune Checkpoint Inhibitors (ICI) for Patients With Stage IV Melanoma Diagnosed From 2010 to 2019.

Percentage of patients with newly diagnosed stage IV melanoma who received ICI in the first-line setting from 2010 to 2019, for (A) all patients, as well as categorized by those with (B) brain and liver metastases and (C) treating hospital type.